In our study, we achieved anti-BCR/ABL antibody intracellular delivery and degrading the BCR/ABL oncoprotein via the Trim-Away pathway, eventually eliminating the pathogenicity of CML cells. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.